Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.

Affiliation

Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Australia; Department of Gastroenterology, Alfred Hospital, Monash University, Melbourne, Australia. Electronic address: [Email]

Abstract

Little is known about the efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab for patients with Crohn's disease (CD) or ulcerative colitis (UC). We analyzed the outcomes of patients receiving vedolizumab along with calcineurin inhibitors.

Keywords

HBI,Response to Therapy,SCCAI,α4 Integrin,